Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Other Events

Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Other Events
Item 8.01Other Events

Story continues below

On December 21, 2018, Acorda Therapeutics, Inc. issued a press release announcing that that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. OFF episodes, also known as OFF periods, are defined as the return of Parkinson’s symptoms that result from low levels of dopamine between doses of oral carbidopa/levodopa, the standard oral baseline Parkinson’s treatment.. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item 8.01.

Item 9.01Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated December 21, 2018

ACORDA THERAPEUTICS INC Exhibit
EX-99.1 2 acor-ex991_14.htm PRESS RELEASE acor-ex991_14.htm EXHIBIT 99.1       MEDIA CONTACT: Tierney Saccavino (917) 783-0251 [email protected] INVESTOR RELATIONS CONTACT: Felicia Vonella (917) 826-3427 [email protected]     FOR IMMEDIATE RELEASE   Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)     • First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinson’s Taking Carbidopa/Levodopa   • Expected to be Available by Prescription in First Quarter 2019   • Based on Innovative ARCUS® Technology Platform for Inhaled Drug Delivery   • Conference Call on Monday,…
To view the full exhibit click here

About Acorda Therapeutics,Inc. (NASDAQ:ACOR)

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson’s disease, chronic post-stroke walking deficits and migraine.

An ad to help with our costs